3 news items
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
ABBV
18 Jun 24
patients. Financial support might also include reimbursement for out-of-pocket costs related to IV administration. For those with limited or no health
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
ABBV
CERE
29 May 24
investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
ABBV
CI
CVS
26 Apr 24
the list of drugs it recommends insurers reimburse.
Price Action: CI shares are down 0.07% at $354.25 at the last check Friday.
Image: Phoenix Locklear from Pixabay
- Prev
- 1
- Next